encorafenib,binimetinib
pfizer,ono pharma,pierre fabre
['nsclc', 'lcsm,(-blcsm)', 'binimetinib', 'encorafenib', 'sclc']
lead author of : "overall, this shows efficacy for both first-line and second-line use of encorafenib and binimetinib for patients with brafv600e-mutant metastatic nsclc." read the paper: #asco23 #lcsm 
@ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, & @JCOPO_ASCO.